Pilot field trial of the EG95 vaccine against ovine cystic echinococcosis in Rio Negro, Argentina: Humoral response to the vaccine

Abstract

Cystic echinococcosis is endemic in the Rio Negro province of Argentina and, for this, a control program using praziquantel in dogs was developed from 1980. The transmission rate to humans and sheep has decreased significantly, however transmission persists. In 2009 the vaccination of sheep with EG95 was incorporated in some areas of the province. The objective of the study was to evaluate the humoral responses to the vaccine EG95. Lambs received two vaccinations with the EG95 vaccine followed by a single booster injection when the animals were 1-1.5 years of age. Blood samples from 6 vaccinated groups and 4 no vaccinated sheep were obtained for determination of antibody titles against EG95 protein. Anti-EG95 responses were determined as described by Heath and Koolaard, 2012. Responses were evaluated from 331 animals. Median ELISA absorbance values in vaccinated group was 0.828, and in non-vaccinated groups was 0.218. EG95 antibody responses in sheep from different cohorts of non-immunized control groups and vaccinated groups reveal the sustained increase in response seen in animals following the third immunization. (p< 0.0001). Significant differences are also evidenced in ANOVA test (p< 0.001). An anti-EG95 antibody response was induced in all groups of immunized sheep, 4 times higher (0.828) than the mean observed in the control groups (0.218). Data described here indicate that following a third vaccination with the EG95 vaccine at 1 year of age the specific IgG responses detected in the serum of sheep increased to a level greater than that seen following the second immunization and that this response was maintained longitudinally over time, for at least 5 years.